Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. - Wikidata - wikimedia - TriplyDB

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.

http://www.wikidata.org/entity/Q37627874

about

Pharmacogenomics and cardiovascular disease Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty.Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects Personalized approaches to clopidogrel therapy: are we there yet?Aspirin and clopidogrel alter core temperature and skin blood flow during heat stress.Clinically relevant genetic variations in drug metabolizing enzymes.Functional genomics applied to cardiovascular medicine.Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials.Relative Copy Number Variations of CYP2C19 in South Indian Population Current genomics in cardiovascular medicine Adenosine A2A receptor agonists with potent antiplatelet activity.Clinical application of high throughput molecular screening techniques for pharmacogenomics.Predicting clopidogrel response using DNA samples linked to an electronic health record.Pharmacogenetic testing: Current Evidence of Clinical Utility.Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response.Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy Pharmacogenetics and human genetic polymorphisms.Nonresponders to clopidogrel: pharmacokinetics and interactions involved.Personalized echocardiography: clinical applications of advanced echocardiography and future directions.A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?The role of pharmacogenetics in nonmalignant gastrointestinal diseases.Genetic determinants of response to cardiovascular drugs.Pharmacogenetics in cardiovascular disorders: an update on the principal drugs.Pharmacogenomics of oral antiplatelet drugs.Review of clopidogrel dose escalation in the current era of potent P2Y12 inhibitors.Characterization of the genetic profile of CYP2C19 in two South African populations.Pharmacogenetics at 50: genomic personalization comes of age.Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study.Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients.Distribution of ABCB1, CYP3A5, CYP2C19, and P2RY12 gene polymorphisms in a Mexican Mestizos population.

P2860

Q26997380-697E207E-2468-4DF8-92D0-73D04837EA2D Q33704998-DEE047E7-4132-4413-9F21-62D4DFE1414C Q33963651-E6B7A8CF-D85D-4FB5-9DCC-1F4C1D7D4AF1 Q34131354-82006195-BC4E-415C-8FAB-682AA83D3689 Q34150640-E1DDF003-9D8B-46E2-9394-00912D43B943 Q34186272-E6F73186-871F-4B6E-81CA-00149E50E743 Q34460548-F8DA68C8-3080-41A5-A1FB-F99748F000E3 Q34470624-08D73C92-2CF4-413E-BB2F-5B7AD52875DB Q35032378-8CF9DCDE-CB0C-4932-9763-3B4775B0E4EC Q35110769-996FEE66-0CF2-456A-B7FD-A6B96FA2BBAB Q35846595-60430C00-AFB5-4781-ACC2-9E5DE205731F Q35985453-7E645E6A-84E6-4DFB-B429-2ECC81F1C729 Q36076189-2C55AB63-0B67-41B5-A455-809BF2010142 Q36186424-AE5908E1-12B6-4BE7-A941-6F7550717360 Q36371663-70A6F79D-C267-4E94-890C-036BC9C07A93 Q36441517-7FC2C40C-7226-4B5D-A899-09AA862FB739 Q36753929-F5FE03EA-CC5E-42D7-A3DC-811EF7E3F666 Q37151528-2D90ABFD-09C2-4ACF-8C69-660C8E6C598E Q37167282-EF86BD96-0F4B-4780-8116-6CF3B38077B4 Q37388236-2C68A919-99C7-4BA0-A007-46F5B2821483 Q37735146-B9D07713-9065-4581-A326-5BFA3C2833CE Q37772183-DACCDD96-5CD5-4461-8154-78A6027A1236 Q37786622-F679E4D5-C222-497D-A163-4187AAE1DD11 Q37818213-F0DBA043-8BEE-4489-AE9A-5913D239E1C9 Q37908891-D645AF31-A25D-4FD7-B473-95E14F8F3C62 Q37981892-120B1528-247C-40E9-901D-659725BFFA7D Q37989811-9E993986-C833-44E2-89DA-E461F8A81472 Q38094070-EC776F9F-4FDA-4980-BAE6-9431F7549FFC Q38195628-55A0DC40-ED20-4ADA-8A54-B6BB2C3650F8 Q38532527-5517AF67-783D-4250-BED4-74ADFA0445F3 Q39667176-4F287ED2-D72C-4C33-944D-D18FDE4F5307 Q40165805-1D1BA2AB-24BC-4E72-8BB8-EB487323AE8E Q42961046-6CD0CB33-5153-44D8-8FD6-2A20A78CBC56 Q43121565-6215000A-2064-47A7-AE90-DF211D41DA75 Q50940254-C0FFABAF-09E3-4647-B535-B671E777151A Q53833189-5CC0A303-A7EF-42E5-B5A2-D8003CE89131

P2860

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.

http://www.wikidata.org/entity/Q37627874

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Clopidogrel pharmacogenomics a ...... ition: US FDA recommendations.

@en

Clopidogrel pharmacogenomics a ...... ition: US FDA recommendations.

@nl

type

label

Clopidogrel pharmacogenomics a ...... ition: US FDA recommendations.

@en

Clopidogrel pharmacogenomics a ...... ition: US FDA recommendations.

@nl

prefLabel

Clopidogrel pharmacogenomics a ...... ition: US FDA recommendations.

@en

Clopidogrel pharmacogenomics a ...... ition: US FDA recommendations.

@nl

P1433

Q37627874-5320B445-87FB-43AB-8BE7-FC400ADE5DAF

P1476

Q37627874-5AE9BD68-316B-461F-86F2-32E1986261EA

P2093

Q37627874-581D5ECE-F252-478D-84E3-0FD882AB8E65

Q37627874-C5604481-87E7-46F6-9A7B-B0B535C1666F

Q37627874-D8F58D8B-88F7-465B-B626-9FAA25DB5ECC

Q37627874-FBA33E63-8E0D-475C-BB0E-2307720E13CD

P2860

Q37627874-0065DDA8-7B89-42B1-A813-263D75BD174D

Q37627874-01FBAE26-8158-444A-B41C-5524BF66ADC1

Q37627874-1035296E-B1A3-4F34-A646-9A35D0679E80

Q37627874-14F7E74E-29C0-4C4D-96F7-C80A45D77483

Q37627874-1640491A-62B2-40C2-9B09-925763E28B3B

Q37627874-1B1DD03B-53FB-4A0D-9101-11DED3D6623E

Q37627874-1BBC1C83-EFA0-4A00-AA1E-940CAC0397CB

Q37627874-1C575611-6050-4A88-9C4C-945A776DE22A

Q37627874-29BA69BE-0896-4D7B-B56D-F09099DAFBA6

Q37627874-2AFFCAC8-FAC4-424B-931D-BC37CE5007BE

P304

Q37627874-69AC83AC-4211-46E3-8DF7-8BBA3C648562

P31

Q37627874-A10BA582-FB75-4EB9-B217-FCEC22D6450D

P356

Q37627874-4A126AA3-FD1D-4C3C-8BCF-8C2A23CD77E6

P433

Q37627874-76D17B92-82FB-4FE6-BCD3-76AE41BD6B3A

P478

Q37627874-65524A58-ACCF-48EF-A23F-D1EB34568031

P577

Q37627874-1FE7E4D1-6828-494D-ABEB-682C764AA373

P5875

Q37627874-CE5655FF-5360-43FA-B902-2002D9CAD6D3

P698

Q37627874-A5F8E6A6-9E59-4F3C-BB01-FA7BFCA89EA9

P921

Q37627874-54172E79-A33B-44E0-A2F8-BC7018530D79

Q37627874-70A0B824-AA91-4D7B-80EB-7A8FBD58F8EB

P356

P1433

Pharmacogenomics

P1476

Clopidogrel pharmacogenomics a ...... ition: US FDA recommendations.

@en

P2093

Craig R Lee

http://www.w3.org/2001/XMLSchema#string

George A Stouffer

http://www.w3.org/2001/XMLSchema#string

Howard L McLeod

http://www.w3.org/2001/XMLSchema#string

Kyle J Ellis

http://www.w3.org/2001/XMLSchema#string

P2860

Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

Platelet function testing in cardiovascular diseases

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

P304

1799-1817

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.09.143

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38069142

http://www.w3.org/2001/XMLSchema#string

P698

19891556

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics